

AMENDMENT TO THE CLAIMS

1-77. (Cancelled)

78. (Currently amended) A method of treating a patient with breast cancer, bladder cancer or prostate cancer comprising administering to the patient an effective amount of an agent that inhibits binds to a peptide or polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

79. (Previously presented) The method of claim 78, wherein the agent is an antibody.

80. (Previously presented) The method of claim 79, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

81. (Previously presented) The method of claim 80, wherein the antibody is a monoclonal antibody.

82. (Previously presented) The method of claim 80 wherein the antibody is a polyclonal antibody.

83. (Currently amended) The method of claim 80, wherein the antibody is conjugated to a radionucleotideradionuclide.

84. (Previously presented) The method of claim 80, wherein the antibody is linked to a chemotherapeutic agent.

85. (Canceled) The method of claim 78, wherein the cancer is bladder cancer, breast cancer or prostate cancer.

86. (Currently amended) The method of claim 78, wherein the agent inhibits binds to a polypeptide encoded by SEQ ID NO: 3, SEQ ID NO: 83 or SEQ ID NO: 85 or a fragment thereof.

87. (Currently amended) A method of treating a breast cancer, bladder cancer or prostate cancer cell comprising administering to the cell an effective amount of an agent that inhibits binds to a peptide or polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

88. (Previously presented) The method of claim 87, wherein the agent is an antibody.

89. (Previously presented) The method of claim 88, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

90. (Previously presented) The method of claim 88, wherein the antibody is a monoclonal antibody.

91. (Previously presented) The method of claim 88, wherein the antibody is a polyclonal antibody.

92. (Currently amended) The method of claim 88, wherein the antibody is conjugated to a radionuclotideradionuclide.

93. (Previously presented) The method of claim 88, wherein the antibody is linked to a chemotherapeutic agent.

94. (Previously presented) The method of claim 87, wherein the cell is in a patient.